Each person will take the assigned tablet twice daily for about four months. During this time, they will complete a simple questionnaire called the Comprehensive Pain Assessment Tool Short Form (COMPAT‑SF) to record how much pain they feel, and another survey called the Short Form 36 (SF‑36) to evaluate overall well‑being. Blood samples will be taken to measure a protein linked to inflammation, known as high‑sensitivity C‑reactive protein (hs‑CRP), and the amount of opioid medication used will be expressed as oral morphine equivalents (OME). These checks are done at regular clinic visits, but no detailed technical procedures are required from the participants.

Safety is closely watched throughout the trial; doctors will look for any stomach irritation, bleeding, kidney changes, heart problems, or liver issues that might arise. Any unwanted effects are recorded and evaluated to ensure the treatment is well tolerated. The information gathered will help determine if the medication offers a meaningful benefit for people living with this condition.

Participants in the study will receive either tocilizumab or a placebo through an infusion, which is a method of delivering medication directly into the bloodstream. The study will last for about 24 weeks, during which participants will have regular check-ups to monitor their health and any changes in their symptoms. The goal is to determine if tocilizumab can significantly reduce pain and improve physical functioning compared to the placebo.

Throughout the study, various assessments will be conducted to measure the impact of the treatment on pain levels and quality of life. These assessments will help researchers understand the potential benefits of tocilizumab for people with chronic pancreatitis. The study will also track the use of pain relief medications and any side effects experienced by participants to ensure a comprehensive evaluation of the treatment’s safety and effectiveness.

Participants in the study will be randomly assigned to receive either the metamizole medication or a placebo, which looks like the medication but does not contain the active ingredient. This is a double-blind study, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results. The study will take place over a period of four weeks, during which participants will record their daily pain levels using a simple numerical scale from 0 (no pain) to 10 (worst pain imaginable).

The main goal is to see if metamizole can effectively reduce the average daily pain intensity. Additionally, the study will look at other factors such as the number of pain-free days, the amount of additional pain medication needed, and overall patient satisfaction with the treatment. The study is expected to conclude by July 2025.